Peter de Waele
Vorstandsvorsitzender bei Advanced Therapies Consulting Limited
Profil
Peter de Waele is the founder of Xcellentis NV, which was founded in 2001, where he held the title of Chief Operating Officer in 2006.
He is currently the Managing Director at Advanced Therapies Consulting Limited.
Dr. de Waele's former positions include Chief Therapeutics Officer at Fujirebio Europe NV, Assistant Professor at Ghent University in 1986, and Vice President-Research & Development at Celyad Oncology SA from 2010 to 2017.
Dr. de Waele received his graduate and doctorate degrees from Ghent University.
Aktive Positionen von Peter de Waele
| Unternehmen | Position | Beginn |
|---|---|---|
| Advanced Therapies Consulting Limited | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Peter de Waele
| Unternehmen | Position | Ende |
|---|---|---|
| CELYAD ONCOLOGY SA | Technik-/Wissenschafts-/F&E-Leiter | - |
| Xcellentis NV | Gründer | 01.01.2006 |
| Ghent University | Corporate Officer/Principal | 01.01.1986 |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Corporate Officer/Principal | - |
Ausbildung von Peter de Waele
| Ghent University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
| Xcellentis NV | Health Technology |
| Advanced Therapies Consulting Limited |
